ストックスクリーナーアプリを入手
31.30
1.86%
0.605
前日終値:
$30.70
開ける：
$31.35
24時間の取引高:
1.65M
Relative Volume:
0.45
時価総額：
$3.52B
収益：
-
当期純損益:
$-99.15M
株価収益率:
-33.66
EPS:
-0.93
ネットキャッシュフロー:
$-74.25M
1週間 パフォーマンス:
+2.86%
1か月 パフォーマンス:
+15.99%
6か月 パフォーマンス:
-3.96%
1年 パフォーマンス:
-45.14%
1日の値動き範囲:
$30.67
$31.94
1週間の範囲:
$29.76
$32.10
52週間の値動き範囲:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
名前
Viking Therapeutics Inc
セクター
電話
858-704-4660
住所
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
VKTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
31.30 | 3.39B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.45 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.83 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.24 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.01 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
278.21 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 開始されました | Goldman | Neutral |
| 2025-02-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-07 | 開始されました | Citigroup | Neutral |
| 2024-12-02 | 開始されました | Piper Sandler | Overweight |
| 2024-11-22 | 開始されました | B. Riley Securities | Buy |
| 2024-11-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-09-11 | 開始されました | JP Morgan | Overweight |
| 2024-06-27 | 開始されました | Morgan Stanley | Overweight |
| 2024-05-16 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 繰り返されました | Oppenheimer | Outperform |
| 2024-03-07 | 開始されました | Jefferies | Buy |
| 2024-02-28 | 繰り返されました | Oppenheimer | Outperform |
| 2023-05-31 | 再開されました | ROTH MKM | Buy |
| 2023-03-28 | 繰り返されました | Maxim Group | Buy |
| 2023-03-17 | 開始されました | Stifel | Buy |
| 2021-07-29 | 再開されました | BTIG Research | Buy |
| 2021-05-25 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 開始されました | BMO Capital Markets | Outperform |
| 2020-05-05 | 開始されました | Chardan Capital Markets | Buy |
| 2020-05-01 | 開始されました | BTIG Research | Buy |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-25 | 開始されました | Stifel | Buy |
| 2019-03-29 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 繰り返されました | Maxim Group | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Mkt Perform |
| 2018-12-12 | 開始されました | B. Riley FBR | Buy |
| 2018-11-19 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-09-18 | 繰り返されました | Maxim Group | Buy |
| 2018-09-18 | 繰り返されました | Raymond James | Outperform |
| 2018-07-20 | 開始されました | SunTrust | Buy |
| 2018-06-28 | 開始されました | Raymond James | Outperform |
| 2018-06-01 | 繰り返されました | Laidlaw | Buy |
| 2018-05-31 | 繰り返されました | Maxim Group | Buy |
| 2018-03-26 | 再開されました | H.C. Wainwright | Buy |
| 2017-11-28 | 繰り返されました | Maxim Group | Buy |
| 2017-11-21 | 開始されました | ROTH Capital | Buy |
すべてを表示
Viking Therapeutics Inc (VKTX) 最新ニュース
H.C. Wainwright Reiterates a Buy Rating on Viking Therapeutics (VKTX), Sets a $102 PT - Insider Monkey
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts - Nasdaq
VKTX August 29th Options Begin Trading - Nasdaq
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies - Seeking Alpha
Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results - Insider Monkey
Better Growth Buy: Eli Lilly vs. Viking Therapeutics - Yahoo Finance
This Insider Has Just Sold Shares In Viking Therapeutics - simplywall.st
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? - MSN
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity - The Motley Fool
Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts (NASDAQ:VKTX) - Seeking Alpha
August 22nd Options Now Available For Viking Therapeutics (VKTX) - Nasdaq
Viking Therapeutics, Inc.(NasdaqCM: VKTX) added to Russell Midcap Value Index - MarketScreener
Viking Therapeutics (VKTX): A High-Risk, High-Reward Biotech Play with Institutional Backing - AInvest
Viking Therapeutics (VKTX): Riding Clinical Catalysts in a Post-Danuglipron World - AInvest
Why This Weight Loss Drug Company's Stock Surged Today - AOL.com
Viking Therapeutics stock maintains buy rating as phase 3 trials begin - Investing.com
VKTX Initiates Phase 3 Study on Obesity Candidate VK2735 - Yahoo Finance
Viking's New Obesity Drug Enters Final Testing Phase: 14.7% Weight Loss in Earlier Trial Sparks Interest - Stock Titan
Was Jim Cramer Right to Favor Another Stock Over Viking Therapeutics (VKTX)? - MSN
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. - Yahoo Finance
(VKTX) Proactive Strategies - news.stocktradersdaily.com
Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200% - TipRanks
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - MSN
Viking Therapeutics (VKTX) Rises on Expected Developments - MSN
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - MSN
We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely - Yahoo Finance
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - AOL.com
Investors Are Gobbling Up Shares of These 10 Firms - Insider Monkey
Viking Therapeutics (VKTX) to Participate in B. Riley's Montreal Meeting | VKTX Stock News - GuruFocus
Jim Cramer Nailed These 11 Stock Predictions - Insider Monkey
1 Stock Down 34% This Year to Buy and Hold - AOL.com
Transcript : Viking Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 11 - marketscreener.com
July 25th Options Now Available For Viking Therapeutics (VKTX) - Nasdaq
(VKTX) Investment Analysis - news.stocktradersdaily.com
Viking Therapeutics at Jefferies Conference: Promising Weight Loss Drug - Investing.com
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - sharewise
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential - Seeking Alpha
Could Viking Therapeutics Become the Next Eli Lilly? - The Globe and Mail
3 Best Growth Stocks to Buy in June - The Motley Fool
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside? - MSN
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Yahoo Finance
SA analyst upgrades: NVDA, DJT, VKTX, BRK.A, BEAM (NVDA:NASDAQ) - Seeking Alpha
Viking Therapeutics: Obesity Candidates Must Prove Their Edge As Market Matures (Upgrade) - Seeking Alpha
Viking Therapeutics to Participate at Upcoming Investor Conferen - GuruFocus
Viking Therapeutics to Participate at Upcoming Investor Conferences | VKTX Stock News - GuruFocus
Viking Therapeutics to Participate at Upcoming Investor Conferences – Company Announcement - Financial Times
Viking Therapeutics Inc (VKTX) 財務データ
収益
当期純利益
現金流量
EPS
Viking Therapeutics Inc (VKTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 03 '25 |
Sale |
27.76 |
4,266 |
118,428 |
168,660 |
| Mancini Marianna | Chief Operating Officer |
Jul 03 '25 |
Sale |
27.77 |
4,266 |
118,473 |
377,535 |
3.40%
1.60%
大文字化:
|
ボリューム (24 時間):